First test of new drug combo for rare bone cancer
NCT ID NCT01407198
Summary
This study tested whether adding an oral drug called nilotinib to standard radiation therapy was safe for people with high-risk chordoma, a rare type of bone cancer. The main goal was to find the highest safe dose of nilotinib when given alongside radiation. Researchers hoped the drug might help radiation work better against the tumor without causing too many side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.